Indivior Pharmaceuticals, Inc. (INDV)
34.75
-0.55
(-1.56%)
USD |
NASDAQ |
Aug 28, 14:20
Indivior Pharmaceuticals Cash from Operations (Quarterly) : 228.52M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 228.52M |
| March 31, 2026 | -9.00M |
| December 31, 2025 | -226.38M |
| September 30, 2025 | -41.78M |
| June 30, 2025 | 165.91M |
| March 31, 2025 | 75.00M |
| December 31, 2024 | -16.85M |
| September 30, 2024 | 3.075M |
| June 30, 2024 | 86.88M |
| March 31, 2024 | -37.00M |
| December 31, 2023 | -280.40M |
| September 30, 2023 | 21.78M |
| June 30, 2023 | -18.74M |
| March 31, 2023 | -36.00M |
| December 31, 2022 | -16.84M |
| September 30, 2022 | 56.59M |
| June 30, 2022 | 23.70M |
| March 31, 2022 | -75.00M |
| December 31, 2021 | 164.34M |
| September 30, 2021 | 26.89M |
| June 30, 2021 | 70.86M |
| March 31, 2021 | 89.00M |
| December 31, 2020 | -72.28M |
| Date | Value |
|---|---|
| September 30, 2020 | 28.11M |
| June 30, 2020 | -4.046M |
| March 31, 2020 | -146.00M |
| December 31, 2019 | 39.97M |
| September 30, 2019 | 39.00M |
| June 30, 2019 | -61.70M |
| March 31, 2019 | 135.00M |
| December 31, 2018 | 88.26M |
| September 30, 2018 | 111.95M |
| June 30, 2018 | 74.44M |
| March 31, 2018 | 25.00M |
| December 31, 2017 | 61.01M |
| September 30, 2017 | 47.34M |
| June 30, 2017 | 126.08M |
| March 31, 2017 | 60.00M |
| December 31, 2016 | 142.26M |
| September 30, 2016 | 112.52M |
| June 30, 2016 | 85.74M |
| March 31, 2016 | 97.00M |
| December 31, 2015 | 51.65M |
| September 30, 2015 | 51.68M |
| June 30, 2015 | 52.95M |
| March 31, 2015 | 165.00M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Supernus Pharmaceuticals, Inc. | -4.81M |
| Liquidia Corp. | 80.24M |
| Corcept Therapeutics, Inc. | 33.54M |
| Amneal Pharmaceuticals, Inc. | -21.24M |
| Prestige Consumer Healthcare, Inc. | 70.79M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -7.942M |
| Cash from Financing (Quarterly) | -172.64M |
| Free Cash Flow | -119.51M |
| Free Cash Flow Per Share (Quarterly) | 1.787 |
| Free Cash Flow to Equity (Quarterly) | 221.58M |
| Free Cash Flow to Firm (Quarterly) | 223.11M |
| Free Cash Flow Yield | -2.71% |